| Year |
Citation |
Score |
| 2019 |
Batukbhai B, Jiang S, Bernhardt E, Muller K, Cao X, Gui J, DiFlorio-Alexander R, Chamberlin, Schwartz G, Paulsen K, Pogue B, Kaufman P. Abstract P6-02-02: Near-infrared spectral tomography (NIRST): A prognostic assessment tool for predicting residual cancer burden (RCB) during neoadjuvant chemotherapy (NAC) in breast cancer (BC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-02-02 |
0.342 |
|
| 2018 |
Bernhardt E, Jiang S, Muller KE, Batukbhai BDO, Gui J, diFlorio-Alexander R, Chamberlin MD, Schwartz GN, Paulsen KD, Pogue BW, Kaufman PA. Correlation of near-infrared spectral tomography (NIRST) with residual cancer burden (RCB) for prognostic assessment subsequent to neoadjuvant chemotherapy (NAC) in breast cancer. Journal of Clinical Oncology. 36: e12655-e12655. DOI: 10.1200/Jco.2018.36.15_Suppl.E12655 |
0.331 |
|
| 2015 |
Andrew AS, Gui J, Hu T, Wyszynski A, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Ekstrom RM, Li Z, Zens MS, Borsuk M, Moore JH, Karagas MR. Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study. Bju International. 115: 238-47. PMID 24666523 DOI: 10.1111/Bju.12641 |
0.314 |
|
| 2015 |
Kaufman P, Jiang S, diFlorio-Alexander R, Gui J, Pogue BW, Paulsen KD. Pre-treatment Near-Infrared Spectral Tomography (NIRST) to predict pathologic complete response to neoadjuvant chemotherapy (NAC) in women with locally advanced breast cancer (LABC). Journal of Clinical Oncology. 33: 1047-1047. DOI: 10.1200/Jco.2015.33.15_Suppl.1047 |
0.312 |
|
| 2015 |
Chamberlin MD, Miller TW, Bean JR, Barth RJ, Rosenkranz KM, Marotti JD, Gemery JM, Gui J. Abstract OT1-2-01: Circulating tumor DNA in plasma as a surrogate for tumor biopsy to identify tumor genetic alterations in patients with multi-focal metastatic breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Ot1-2-01 |
0.317 |
|
| 2014 |
Jiang S, Pogue BW, Gui J, Jermyn M, Kaufman PA, Paulsen KD. Pre-treatment total hemoglobin in breast cancer is a predictor for complete response to neoadjuvant chemotherapy Ieee Transactions On Biomedical Engineering. DOI: 10.1364/Biomed.2014.Bw4B.2 |
0.334 |
|
| 2012 |
Andrew AS, Hu T, Gu J, Gui J, Ye Y, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Mason RA, Morlock EV, Zens MS, Li Z, Moore JH, et al. HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer. Plos One. 7: e51301. PMID 23284679 DOI: 10.1371/Journal.Pone.0051301 |
0.323 |
|
| 2012 |
Wolf B, Schwarzer A, Côté AL, Hampton TH, Schwaab T, Huarte E, Tomlinson CR, Gui J, Fisher JL, Fadul CE, Hamilton JW, Ernstoff MS. Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine. Plos One. 7: e50221. PMID 23226513 DOI: 10.1371/Journal.Pone.0050221 |
0.307 |
|
| 2011 |
Gui J, Moore JH, Kelsey KT, Marsit CJ, Karagas MR, Andrew AS. A novel survival multifactor dimensionality reduction method for detecting gene-gene interactions with application to bladder cancer prognosis. Human Genetics. 129: 101-10. PMID 20981448 DOI: 10.1007/S00439-010-0905-5 |
0.302 |
|
| 2011 |
Andrew AS, Gui J, Moore JH, Karagas MR, Pendleton E, Schned AR, Mason RA, Wyszynski A, Tanyos SA, Kelsey KT, Marsit CJ, Zens MS. Abstract A66: Apoptosis, cell cycle, DNA repair, immune, and metabolism pathway SNPs modify bladder cancer risk, recurrence, and survival Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-A66 |
0.328 |
|
| 2010 |
Celaya MO, Berke EM, Onega TL, Gui J, Riddle BL, Cherala SS, Rees JR. Breast cancer stage at diagnosis and geographic access to mammography screening (New Hampshire, 1998-2004). Rural and Remote Health. 10: 1361. PMID 20438282 DOI: 10.22605/Rrh1361 |
0.304 |
|
| 2009 |
Andrew AS, Gui J, Sanderson AC, Mason RA, Morlock EV, Schned AR, Kelsey KT, Marsit CJ, Moore JH, Karagas MR. Bladder cancer SNP panel predicts susceptibility and survival. Human Genetics. 125: 527-39. PMID 19252927 DOI: 10.1007/S00439-009-0645-6 |
0.31 |
|
| Show low-probability matches. |